mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients

Jennie H. Kwon, Mark W. Tenforde, Manjusha Gaglani, H. Keipp Talbot, Adit A. Ginde, Tresa McNeal, Shekhar Ghamande, David J. Douin, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Sean D. Caspers, Matthew C. Exline, Mena BotrosMichelle N. Gong, Alex Li, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Akram Khan, Catherine L. Hough, Laurence W. Busse, Abhijit Duggal, Jennifer G. Wilson, Cynthia Perez, Steven Y. Chang, Christopher Mallow, Randal Rovinski, Hilary M. Babcock, Adam S. Lauring, Laura Felley, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, Kelsey N. Womack, Christopher J. Lindsell, Kimberly W. Hart, Adrienne Baughman, Samantha M. Olson, Stephanie Schrag, Miwako Kobayashi, Jennifer R. Verani, Manish M. Patel, Wesley H. Self

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


BACKGROUND: The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. METHODS: We conducted a 21-site case-control analysis of 10 425 adults hospitalized in March to December 2021. Cases were hospitalized with COVID-19; controls were hospitalized for an alternative diagnosis (severe acute respiratory syndrome coronavirus 2-negative). Participants were classified as follows: SOT recipient (n = 440), other immunocompromising condition (n = 1684), or immunocompetent (n = 8301). The VE against COVID-19-associated hospitalization was calculated as 1-adjusted odds ratio of prior vaccination among cases compared with controls. RESULTS: Among SOT recipients, VE was 29% (95% confidence interval [CI], -19% to 58%) for 2 doses and 77% (95% CI, 48% to 90%) for 3 doses. Among patients with other immunocompromising conditions, VE was 72% (95% CI, 64% to 79%) for 2 doses and 92% (95% CI, 85% to 95%) for 3 doses. Among immunocompetent patients, VE was 88% (95% CI, 87% to 90%) for 2 doses and 96% (95% CI, 83% to 99%) for 3 doses. CONCLUSIONS: Effectiveness of COVID-19 mRNA vaccines was lower for SOT recipients than immunocompetent adults and those with other immunocompromising conditions. Among SOT recipients, vaccination with 3 doses of an mRNA vaccine led to substantially greater protection than 2 doses.

Original languageEnglish (US)
Pages (from-to)797-807
Number of pages11
JournalThe Journal of infectious diseases
Issue number5
StatePublished - Sep 13 2022


  • COVID-19
  • SARS-CoV-2
  • immunocompromised
  • solid organ transplantation
  • vaccine effectiveness

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients'. Together they form a unique fingerprint.

Cite this